Sarcopenia is a disease recognized by the WHO on the international classification of diseases ICD (M62.8). Its prevalence increases with age and chronic pathologies. Thus, it affects approximately 10% of people over 65 years old, 50% of those over 80 years old. Its prevalence is increased in chronic pathologies of the musculoskeletal system affecting 30% of patients. During rheumatological inflammatory pathologies (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies), alterations in body composition linked to loss of mobility, inflammation, insulin resistance occur early. Muscle loss associated with an increase in adipose tissue are observed and define the phenotype of sarcopenic adiposity which contributes to cardiovascular and metabolic comorbidities and increased morbidity and mortality. In chronic inflammatory rheumatism, the management of cardio-metabolic comorbidities (sarcopenic adiposity, metabolic syndrome, cardiovascular risk, fracture osteoporosis) is therefore one of the major challenges. This is why the research activity aims to explore sarcopenia, metabolic disorders and associated comorbidities in chronic inflammatory diseases of the musculoskeletal system. Such knowledge is essential for the development of innovative targeted, personalized and multimodal therapeutic and preventive strategies based on biotherapies, nutrition and physical activity.

Research activity

Characterization of different phenotypes of sarcopenia in chronic inflammatory joint and muscle diseases (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies): changes in muscle mass, fat mass, and bone mass, associated metabolic disorders and cardiovascular comorbidities, energy expenditure, taking into account the effect of treatments during longitudinal follow-up.

Identification of the pathophysiological mechanisms of sarcopenia and therapeutic targets in joint and systemic inflammatory conditions: muscle lipotoxicity, impact of cytokine inhibitors and diet, identification of a biological signature related to muscle lipotoxicity.

Development of diagnostic and monitoring tools: validation of sarcopenia biomarker(s) in a cohort of patients, designing predictive algorithms for a personalized prevention and treatment strategy.

Development of new therapeutic strategies combining targeted biotherapies, nutrition, and physical activity.

Most notable publications

• Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, Frayssac T, Mathieu S, Malochet-Guinamand S, Soubrier M. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J  Cachexia Sarcopenia Muscle. 2017 Aug;8(4):639-646.
   
• Tournadre A, Pereira B, Dubost JJ, Rincheval N, Rat AC, Combe B, Soubrier M. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):296-302.
   
• Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. RMD Open. 2017 Nov 1;3(2):e000515.
   
• Marouen S, du Cailar G, Audo R, Lukas C, Vial G, Tournadre A, Barrat E, Ribstein J, Combe B, Morel J, Daien CI. Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls. PLoS One. 2017 Oct 13;12(10):e0186157.
   
• Malochet-Guinamand S, Pereira B, Tatar Z, Tournadre A, Moltó A, Dougados M, Soubrier M. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskelet Disord. 2017 Aug 22;18(1):357.

Other links

• https://www.linkedin.com/in/anne-tournadre-474953a4/
• ASMS